Finally, we propose that NTHL1 should be included in cancer gene panels in clinical diagnostics and clinical practice guidelines should be developed for cancer screening strategies for individuals with pathogenic biallelic NTHL1 variants. This evidence concerns the gene NTHL1 and cancer.